High‐fat‐induced nonalcoholic fatty liver potentiates vulnerability to and the severity of viral hepatitis in a C3H / HeN mouse model

BioFactors ◽  
2021 ◽  
Author(s):  
Ting Wu ◽  
Junjian Hu ◽  
Xiaojing Wang ◽  
Xiaoping Luo ◽  
Hongwu Wang ◽  
...  
Keyword(s):  
Mouse Model ◽  
Fatty Liver ◽  
Viral Hepatitis ◽  
High Fat ◽  
Nonalcoholic Fatty Liver

scholarly journals Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model

Nutrients ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2433
Author(s):  
Hwi-Jin Im ◽  
Seung-Ju Hwang ◽  
Jin-Seok Lee ◽  
Sung-Bae Lee ◽  
Ji-Yun Kang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Mouse Model ◽  
Fatty Liver ◽  
Ethyl Acetate ◽  
Nonalcoholic Fatty Liver Disease ◽  
High Fat Diet ◽  
Fatty Liver Disease ◽  
Ethyl Acetate Fraction ◽  
High Fat ◽  
Nonalcoholic Fatty Liver

The global prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated to be 25% and has continued to increase; however, no drugs have yet been approved for NAFLD treatments. The ethyl acetate fraction of Amomum xanthioides (EFAX) was previously reported to have an anti-hepatic fibrosis effect, but its effects on steatosis or steatohepatitis remain unclear. This study investigated the anti-fatty liver of EFAX using a high-fat diet mouse model. High-fat diet intake for 8 weeks induced hepatic steatosis with mild inflammation and oxidative damage and increased the adipose tissue weight along with the development of dyslipidemia. EFAX treatment significantly ameliorated the steatohepatic changes, the increased weight of adipose tissues, and the altered serum lipid profiles. These observed effects were possibly due to the lipolysis-dominant activity of EFAX on multiple hepatic proteins including sterol regulatory element-binding protein (mSREBP)-1c, peroxisome proliferator-activated receptor (PPAR)-α, AMP-activated protein kinase, and diglyceride acyltransferases (DGATs). Taken together, these results show that EFAX might be a potential therapeutic agent for regulating a wide spectrum of NAFLDs from steatosis to fibrosis via multiple actions on lipid metabolism-related proteins. Further studies investigating clear mechanisms and their active compounds are needed.

scholarly journals Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high‐fat diet in the genetically diverse Collaborative Cross mouse model

2020 ◽  
Vol 34 (6) ◽  
pp. 7773-7785
Author(s):  
Aline Conti ◽  
Volodymyr Tryndyak ◽  
Rose A. Willett ◽  
Barbara Borowa‐Mazgaj ◽  
Anna Watson ◽  
...  
Keyword(s):  
Mouse Model ◽  
Fatty Liver ◽  
High Fat Diet ◽  
Collaborative Cross ◽  
High Fat ◽  
Nonalcoholic Fatty Liver

scholarly journals Effects of alkaline-electrolyzed and hydrogen-rich water, in a high-fat-diet nonalcoholic fatty liver disease mouse model

2018 ◽  
Vol 24 (45) ◽  
pp. 5095-5108 ◽  
Author(s):  
Karen Jackson ◽  
Noa Dressler ◽  
Rotem S Ben-Shushan ◽  
Ari Meerson ◽  
Tyler W LeBaron ◽  
...  
Keyword(s):  
Liver Disease ◽  
Mouse Model ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
High Fat Diet ◽  
Fatty Liver Disease ◽  
High Fat ◽  
Nonalcoholic Fatty Liver

scholarly journals Massa Medicata Fermentata improves fatty liver in high fat diet-fed nonalcoholic fatty liver disease's mouse model

2014 ◽  
Vol 29 (2) ◽  
pp. 23-31 ◽  
Author(s):  
Jong Seong Roh ◽  
Hye Rim Lee ◽  
Ye Ji Ahn ◽  
Mi Chung Yoon ◽  
Soon Shik Shin
Keyword(s):  
Mouse Model ◽  
Fatty Liver ◽  
High Fat Diet ◽  
High Fat ◽  
Nonalcoholic Fatty Liver
Sign in / Sign up

Export Citation Format

Share Document